Optiray (Ioversol)

Optiray is an iodinated contrast agent used in radiographic pathways that require enhanced vascular and tissue delineation.

• Computed Tomography (CT) of the head, chest, abdomen and pelvis: improves lesion detection and anatomic detail.
• Angiography (including cerebral, cardiac and peripheral): provides clear visualization of blood‑vessel lumen.
• Urography and intravenous pyelogram (IVP): outlines the urinary collecting system for diagnostic assessment.

• Ioversol is a non‑ionic, low‑osmolality iodine‑based compound that distributes rapidly in the extracellular fluid after intravenous injection. Its high atomic number absorbs X‑ray photons, increasing radiodensity of blood and tissues, which produces enhanced contrast on CT and fluoroscopic images without interacting with specific cellular receptors.

Adverse reactions to Optiray may range from mild to severe and should be monitored during and after administration.

Common Side Effects

• Warm sensation or flushing at the injection site
• Nausea or mild vomiting
• Headache
• Transient metallic taste
• Mild itching or urticaria
• Low‑grade hypotension

Serious or Rare Side Effects

• Severe hypersensitivity or anaphylactoid reaction
• Acute kidney injury, especially in patients with pre‑existing renal impairment
• Cardiovascular collapse
• Pulmonary edema
• Seizures
• Fatal outcomes in rare cases

Before using Optiray, clinicians should assess patient history and follow recommended safety measures.

• Renal function assessment: evaluate serum creatinine and eGFR, especially in at‑risk patients.
• Allergy history: confirm no prior severe reaction to iodinated contrast.
• Hydration status: ensure adequate pre‑ and post‑procedure hydration to reduce nephrotoxicity risk.
• Concomitant nephrotoxic drugs: consider dose adjustment or alternative imaging if possible.
• Pregnancy and lactation: use only if essential, after risk‑benefit analysis.
• Store at below 25°C: keep in original container, protect from light and moisture.

Optiray may interact with other agents that affect renal function or provoke hypersensitivity.

Major Interactions (Avoid)

• Metformin: risk of lactic acidosis in renal impairment; discontinue before contrast administration.
• High‑dose NSAIDs: may exacerbate contrast‑induced nephropathy.
• Angiotensin‑converting enzyme inhibitors or ARBs: increase risk of renal dysfunction when combined with contrast.

Moderate Interactions (Monitor Closely)

• Diuretics: may alter fluid balance, requiring careful monitoring of hydration.
• Beta‑blockers: can mask early signs of anaphylactoid reactions.
• Thyroid hormones: iodine load may affect thyroid function tests.
• Radiopharmaceuticals: consider timing to avoid overlapping imaging artifacts.
• Other contrast agents: avoid sequential administration without adequate clearance.